title: Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.
abstract: The cellular immunogenicity of formulated plasmid DNA and replication-defective human adenovirus serotype 5 (Ad5) vaccine vectors expressing a codon-optimized human immunodeficiency virus type 1 gag gene was examined in baboons. The Ad5 vaccine was capable of inducing consistently strong, long-lived CD8(+)-biased T-cell responses and in vitro cytotoxic activities. The DNA vaccine-elicited immune responses were weaker than those elicited by the Ad5 vaccine and highly variable; formulation with chemical adjuvants led to moderate increases in the levels of Gag-specific T cells. Increasing the DNA-primed responses with booster doses of either Ad5 or modified vaccinia virus Ankara vaccines suggests a difference in the relative levels of cytotoxic and helper responses. The implications of these results are discussed.
authors.affiliation: Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. danilo_casimiro@merck.com
authors.forename: Danilo R
authors.initials: DR
authors.lastname: Casimiro
authors.forename: Aimin
authors.initials: A
authors.lastname: Tang
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Tong-Ming
authors.initials: TM
authors.lastname: Fu
authors.forename: Robert K
authors.initials: RK
authors.lastname: Evans
authors.forename: Mary-Ellen
authors.initials: ME
authors.lastname: Davies
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Freed
authors.forename: William
authors.initials: W
authors.lastname: Hurni
authors.forename: Jose M
authors.initials: JM
authors.lastname: Aste-Amezaga
authors.forename: Liming
authors.initials: L
authors.lastname: Guan
authors.forename: Romnie
authors.initials: R
authors.lastname: Long
authors.forename: Lingyi
authors.initials: L
authors.lastname: Huang
authors.forename: Virginia
authors.initials: V
authors.lastname: Harris
authors.forename: Denise K
authors.initials: DK
authors.lastname: Nawrocki
authors.forename: Henryk
authors.initials: H
authors.lastname: Mach
authors.forename: Robert D
authors.initials: RD
authors.lastname: Troutman
authors.forename: Lynne A
authors.initials: LA
authors.lastname: Isopi
authors.forename: Krishna K
authors.initials: KK
authors.lastname: Murthy
authors.forename: Karen
authors.initials: K
authors.lastname: Rice
authors.forename: Keith A
authors.initials: KA
authors.lastname: Wilson
authors.forename: David B
authors.initials: DB
authors.lastname: Volkin
authors.forename: Emilio A
authors.initials: EA
authors.lastname: Emini
authors.forename: John W
authors.initials: JW
authors.lastname: Shiver
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000818:Animals; D003673:Defective Viruses / Q000235:genetics* / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D015750:Genes, gag; D015497:HIV-1 / Q000235:genetics*; D010215:Papio; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D016915:AIDS Vaccines